Month: May 2025

PEMBROKE, Bermuda, May 05, 2025 (GLOBE NEWSWIRE) — James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR) reported net income from continuing operations available to common shareholders of $9.0 million ($0.18 per diluted share) and adjusted net operating income1 of $9.1 million ($0.19 per diluted share) for the first quarter of 2025.  Three Months EndedMarch 31,   Three Months EndedMarch 31,($ in thousands, except for share data)   2025     per diluted share     2024     per dilutedshareNet income from continuing operations available to common shareholders $ 9,019     $ 0.18     $ 20,883     $ 0.53  Net loss from discontinued operations2   (1,414 )   $ (0.02 )     (8,105 )   $ (0.18 )Net income available to common shareholders   7,605     $ 0.16       12,778     $ 0.35  Adjusted...

Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2025 financial results and corporate updates. “2025 is a year of execution across a range of high value clinical programs,” said Sanjiv...

Signed 10 deals in the first quarter, highlighted by 4 with new customers Paid down $17 million of debt and repurchased $10 million of common stock Generated $57 million in cash from operations   SAN JOSE, Calif., May 05, 2025 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA) (the “Company” or “Adeia”) today announced financial results for the first quarter ended March 31, 2025. “We had a strong start to the year with revenue of $87.7 million which was in line with our expectations, and we generated $57.1 million in cash from operations,” said Paul E. Davis, chief executive officer of Adeia. “We closed 10 deals in the first quarter, continuing our momentum from last year. Importantly four of these were new deals in key growth areas such as social media, OTT, and semiconductors. Our commitment to innovation continues as we focus on growth...

First Quarter Revenue Growth of 83% Year-Over-Year to $166.6 million First Quarter Variable Marketing Dollars Increase of 52% Year-Over-Year to $46.9 million Delivers First Quarter Net Income of $8.0 million and Record Adjusted EBITDA of $22.5 millionCAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) — EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced financial results for the first quarter ended March 31, 2025. “2025 is off to a strong start, building on our momentum from last year, and we once again achieved record financial performance across our key financial metrics of revenue, Variable Marketing Dollars or VMD and Adjusted EBITDA,” said Jayme Mendal, CEO of EverQuote. “Our scale and technology are enabling us to build a competitive moat and leverage a data advantage as we extend AI throughout...

Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash RunwayIcovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapy Biomea’s next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities are either being partnered or closedREDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2025, and provided a business update. “In the first quarter of 2025, we executed a focused realignment of our operations to concentrate...

MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Summary & Recent Business Highlights:Total revenue increased 0.3% year-over-year to $61.3 million Gross margin of 74% versus 71% in Q1 2024 Net loss of $3.0 million versus $2.2 million in Q1 2024 Adjusted EBITDA loss of $0.3 million versus positive Adjusted EBITDA of $1.0 million in Q1 2024 Repurchased $10.0 million of stock under the Company’s share repurchase program Expanded launch of Nimbl to include patients with lower extremity conditions, the largest segment of the lymphedema market Completed launch of a new customer...

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report five data readouts across ORIC-944 and ORIC-114 clinical programs over the next 15 months, with potential initiation of registrational trials for both programs in 2026 Cash and investments of approximately $224 million expected to fund operating plan into 2027 SOUTH SAN...

SHOEMAKERSVILLE, Pa., May 05, 2025 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture (“CEA”), today announced that it will host a conference call to review first quarter 2025 results on Tuesday, May 13, 2025 at 8:30 AM ET. A press release containing first quarter 2025 results will be issued before market open that same day. The conference call can be accessed live over the phone by dialing 1-800-343-5172 and entering the conference ID: HYFMQ1. The conference call will also be webcast live and archived on the corporate website at www.hydrofarm.com, under the “Investors” section. About Hydrofarm Holdings Group, Inc.Hydrofarm is a leading independent...

SPARTANBURG, S.C., May 05, 2025 (GLOBE NEWSWIRE) — Denny’s Corporation (the “Company”) (NASDAQ: DENN), owner and operator of Denny’s Inc. (“Denny’s”) and Keke’s Inc. (“Keke’s”), today reported results for its first quarter ended March 26, 2025 and provided a business update on the Company’s operations. Kelli Valade, Chief Executive Officer, stated, “The beginning of the year has presented significant challenges for consumers, which is evident in our results. Our teams have remained focused on executing against our strategic initiatives and winning with our guests, despite these macro headwinds. This included staying true to our Denny’s flagship, by focusing on compelling value, being strategic in reaching new younger demographics through innovative partnerships...